Skip to content

Does Evening Primrose Oil Improve Pruritis (Itching) in a Dialysis Population?

In patients with end stage renal failure on dialysis, does evening primrose oil, compared to omega -3 fish oil and placebo improve pruritis?

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12614000677606
Enrollment
90
Registered
2014-06-26
Start date
2014-07-02
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Pruritis is a common symptom in patients on dialysis and has significant impact on their quality of life. The pathophysiology is not well understood and treatments are not very effective. Evening Primrose Oil has been used successfully in eczema and small studies suggest it may be of benefit in uraemic pruritis.This study is designed to investigate whether in fact Evening Primrose oil does has a beneficial effect on pruritis.

Interventions

Patients with end stage renal failure, undergoing dialysis (in hospital or at home), will be invited to participate. Consenting participants will complete a questionnaire about pruritis (itching). Participants will complete the Polyunsaturated Fatty Acid Food Frequency Questionnaire with an Investigator in a face to face interview. Participants will also complete a 3day dietary recall and Patient Generated Subjective Global Assessment (PGSGA) during the interview. Blood samples will also be take

Patients with end stage renal failure, undergoing dialysis (in hospital or at home), will be invited to participate. Consenting participants will complete a questionnaire about pruritis (itching). Participants will complete the Polyunsaturated Fatty Acid Food Frequency Questionnaire with an Investigator in a face to face interview. Participants will also complete a 3day dietary recall and Patient Generated Subjective Global Assessment (PGSGA) during the interview. Blood samples will also be taken at baseline and post intervention to measure C reactive protein and red blood cell fatty acid status. Also a doubleblinded, randomised placebo controlled trial will be conducted where each participant will be assigned to receive one of three capsule types: * evening primrose oil (omega 6 fatty acids) *fish oil (omega 3 fatty acids) *placebo (vegetable oil) Patients will be randomised to receive 1 of 3 interventions: 1. Active- Evening Primrose Oil, 1gram three times a day, each capsule contains 100mg of gamma-Linolenic acid 2. Active - Omega -3 Fish oil,1 gram three times a day - each capsule contains 53mg EPA and 250mg DHA, with total omega-3 = 348mg The patients will be asked to take three capsules each day for 4 months. Adherence will be monitored by capsule count at the end of the study as well as monitoring of the red cell fatty acid levels. Efficacy of the active groups will be assessed by response to itching, inflammatory markers .

Sponsors

Department of Renal Medicine, WOLLONGONG hOSPITAL
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients on dialysis for 3 months or more

Exclusion criteria

Pregnancy

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026